1.12
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
TScan Therapeutics Shares Fall After BTIG Research Downgrade - MarketScreener
Biotech firm TScan slashes jobs, extends cash runway amid strategic realignment - The Business Journals
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays By Investing.com - Investing.com Australia
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays - Investing.com India
BTIG Research Downgrades TScan Therapeutics to Neutral From Buy - MarketScreener
Needham Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
TScan Therapeutics (TCRX) Analyst Update: Needham Lowers Price T - GuruFocus
Reversal indicators forming on TScan Therapeutics Inc. stockQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.Earnings Growth Report & Precise Swing Trade Entry Alerts - newser.com
Best data tools to analyze TScan Therapeutics Inc. stockDollar Strength & Reliable Intraday Trade Alerts - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com Nigeria
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com UK
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
Trend analysis for TScan Therapeutics Inc. this weekWatch List & Target Return Focused Picks - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesRecession Risk & Low Risk Entry Point Tips - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackExit Point & Weekly Watchlist of Top Performers - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.Weekly Risk Report & High Yield Equity Trading Tips - newser.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Technical signs of recovery in TScan Therapeutics Inc.Chart Signals & Stock Timing and Entry Methods - newser.com
Should you wait for a breakout in TScan Therapeutics Inc.Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Report & Community Trade Idea Sharing - newser.com
Is TScan Therapeutics Inc. still worth holding after the dipBull Run & Technical Pattern Recognition Alerts - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Weekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
자본화:
|
볼륨(24시간):